

US011026791B2

(12) United States Patent

Genovese et al.

(54) FLEXIBLE CANOPY VALVE REPAIR SYSTEMS AND METHODS OF USE

(71) Applicant: MEDTRONIC VASCULAR, INC.,

Santa Rosa, CA (US)

(72) Inventors: Matthew Genovese, Windsor, CA (US);

Jeffrey Sandstrom, Scandia, MN (US); Russell Pribanic, Roxbury, CT (US); Thomas Mcpeak, Caledonia, MN (US); Vania Lee, Circle Pines, MN (US); Dermot O'Brien, Galway (IE); James Calvin Allan, Boise, ID (US)

(73) Assignee: MEDTRONIC VASCULAR, INC.,

Santa Rosa, CA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 55 days.

(21) Appl. No.: 16/352,963

(22) Filed: Mar. 14, 2019

(65) Prior Publication Data

US 2019/0290431 A1 Sep. 26, 2019

Related U.S. Application Data

- (60) Provisional application No. 62/645,306, filed on Mar. 20, 2018.
- (51) Int. Cl.

 A61F 2/24 (2006.01)

 A61B 17/04 (2006.01)

 A61B 17/00 (2006.01)

(10) Patent No.: US 11,026,791 B2

(45) Date of Patent: Jun. 8, 2021

(58) Field of Classification Search

CPC A61F 2/2454; A61F 2/2457; A61F 2/246; A61F 2/2463

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

6,165,183 A 12/2000 Kuehen et al. 6,260,552 B1 7/2001 Mortier et al. (Continued)

FOREIGN PATENT DOCUMENTS

WO 2012068541 A2 5/2012 WO 2017115123 A1 7/2017

OTHER PUBLICATIONS


PCT/US2019/022680, The International Search Report and Written Opinion, dated Aug. 9, 2019, 17pgs.

Primary Examiner — Suba Ganesan (74) Attorney, Agent, or Firm — Meddler Ferro Woodhouse & Mills PLLC

(57) ABSTRACT

A system for treating valvular regurgitation in a heart valve includes a flexible canopy and an elongated tether including an elastic portion and an inelastic portion. When the system is in a deployed configuration, a proximal end of the flexible canopy is coupled to an annulus of the heart valve and a distal end of the elongated tether is coupled to a ventricle. The flexible canopy is configured to overlay a first native leaflet of the heart valve, and tension on the elongated tether is applied and/or adjusted to prevent the first leaflet from prolapsing, to maximize coaptation of the flexible canopy with a second native leaflet of the heart valve, and to minimize regurgitation of the heart valve.

20 Claims, 17 Drawing Sheets



(52)		.01); <i>A61B</i>	2463 (2013.01); A61B 17/0401 2017/00243 (2013.01); A61F 25 (2013.01); A61F 2250/0018 (2013.01)	7,112,207 B2 7,112,219 B2 7,122,043 B2 7,125,420 B2 7,166,126 B2 7,166,127 B2 7,179,282 B2	9/2006 10/2006 10/2006 1/2007 1/2007	Allen et al. Vidlund et al. Greenhalgh et al. Rourke et al. Spence et al. Spence et al. Alferness et al.
(56)		Referen	ces Cited	7,179,291 B2 7,186,264 B2		Rourke et al. Liddicoat et al.
	U.S.	PATENT	DOCUMENTS	7,189,199 B2 7,192,442 B2		McCarthy et al. Solem et al.
	6,269,819 B1		Oz et al.	7,192,443 B2 7,211,110 B2		Solem et al. Rowe et al.
	6,312,447 B1 6,332,893 B1	11/2001 12/2001	Grimes Mortier et al.	7,226,467 B2 7,229,469 B1		Lucatero et al.
	6,355,030 B1		Aldrich et al.	7,229,469 B1 7,247,134 B2		Witzel et al. Vidlund et al.
	6,402,781 B1 6,406,420 B1		Langberg et al. McCarthy et al.	7,270,676 B2 7,288,097 B2	9/2007 10/2007	Alferness et al. Seguin
	6,419,696 B1 6,461,366 B1	7/2002 10/2002	Ortiz et al. Seguin	7,291,168 B2	11/2007	Macoviak et al.
	6,537,314 B2	3/2003	Langberg et al.	7,296,577 B2 7,300,462 B2		Lashinski et al. Swinford et al.
	6,575,971 B2 6,602,288 B1		Hauck et al. Cosgrove et al.	7,309,354 B2 7,311,728 B2		Mathis et al. Solem et al.
	6,619,291 B2 6,626,930 B1		Hlavka et al. Allen et al.	7,311,728 B2 7,311,729 B2		Mathis et al.
	6,629,534 B1		St. Goar et al.	7,311,731 B2 7,314,485 B2		Lesniak et al. Mathis
	6,656,221 B2 6,676,702 B2	12/2003 1/2004	Taylor et al. Mathis	7,316,706 B2	1/2008	Bloom et al.
	6,689,164 B1	2/2004	Seguin et al.	7,351,259 B2 7,351,260 B2		Swinford et al. Nieminen et al.
	6,695,866 B1 6,702,826 B2		Kuehen et al. Liddicoat et al.	7,357,815 B2 7,361,190 B2		Shaoulian et al. Shaoulian et al.
	6,706,065 B2 6,709,456 B2		Langberg et al. Langberg et al.	7,364,588 B2	4/2008	Mathis et al.
	6,718,985 B2	4/2004	Hlavka et al.	7,373,207 B2 7,377,941 B2		Lattouf Rhee et al.
	6,719,767 B1 6,723,038 B1		Kimblad Schroeder et al.	7,381,210 B2	6/2008	Zarbatany et al.
	6,743,239 B1	6/2004	Keuhn et al.	7,381,220 B2 7,396,364 B2		Macoviak et al. Moaddeb et al.
	6,746,471 B2 6,752,813 B2		Mortier et al. Goldfarb et al.	7,404,824 B1 7,431,692 B2		Webler et al. Zollinger et al.
	6,764,510 B2 6,770,083 B2		Vidlund et al. Seguin	7,431,726 B2	10/2008	Spence et al.
	6,770,083 B2 6,790,231 B2		Liddicoat et al.	7,442,207 B2 7,452,375 B2		Rafiee Mathis et al.
	6,793,673 B2 6,797,001 B2		Kowalsky et al. Mathis et al.	7,464,712 B2	12/2008	Oz et al.
	6,797,002 B2	9/2004	Spence et al.	7,473,274 B2 7,485,143 B2		Sater Webler et al.
	6,800,090 B2 6,805,711 B2		Alferness et al. Quijano et al.	7,500,989 B2		Solem et al.
	6,810,882 B2	11/2004	Langberg et al.	7,503,931 B2 7,503,932 B2		Kowalsky et al. Mathis et al.
	6,824,562 B2 6,840,246 B2		Mathis et al. Downing	7,507,252 B2 7,509,959 B2		Lashinski et al. Oz et al.
	6,875,224 B2 6,890,353 B2		Grimes Cohn et al.	7,510,576 B2	3/2009	Langberg et al.
	6,908,478 B2	6/2005	Alferness et al.	7,510,577 B2 7,513,908 B2		Moaddeb et al. Lattouf
	6,913,608 B2 6,926,715 B1		Liddicoat et al. Hauck et al.	7,527,646 B2	5/2009	Rahdert et al.
	6,926,730 B1	8/2005	Nguyen et al.	7,527,647 B2 7,534,204 B2		Spence Starksen et al.
	6,949,122 B2 6,960,229 B2		Adams et al. Mathis et al.	7,534,260 B2 7,536,228 B2		Lattouf Shaolian et al.
	6,962,605 B2 6,964,683 B2		Cosgrove et al. Kowalsky et al.	7,559,936 B2	7/2009	Levine et al.
	6,964,684 B2	11/2005	Ortiz et al.	7,563,267 B2 7,563,273 B2		Goldfarb et al. Goldfarb et al.
	6,966,926 B2 6,976,995 B2	11/2005 12/2005	Mathis et al.	7,569,062 B1	8/2009	Kuehen et al.
	6,978,176 B2	12/2005	Lattouf	7,588,582 B2 7,591,826 B2		Ancora Alferness et al.
	6,986,775 B2 6,989,028 B2		Morales et al. Lashinski et al.	7,604,646 B2 7,608,091 B2		Goldfarb et al. Goldfarb et al.
	6,997,951 B2 7,004,176 B2	2/2006 2/2006	Solem et al.	7,608,120 B2	10/2009	Adams et al.
	7,004,958 B2	2/2006	Adams et al.	7,628,797 B2 7,635,329 B2		Tieu et al. Goldfarb et al.
	7,011,669 B2 7,011,682 B2		Kimblad Lashinski et al.	7,635,386 B1	12/2009	Gammie
	7,037,334 B1	5/2006	Hlavka et al.	7,635,387 B2 7,637,945 B2		Reuter et al. Solem et al.
	7,044,967 B1 7,052,487 B2		Solem et al. Cohn et al.	7,637,946 B2	12/2009	Solem et al.
	7,070,618 B2 7,077,861 B2		Streeter Spence	7,655,015 B2 7,655,040 B2		Goldfarb et al. Douk et al.
	7,077,862 B2	7/2006	Vidlund et al.	7,666,193 B2	2/2010	Starksen et al.
	7,083,628 B2 7,090,695 B2		Bachman Solem et al.	7,666,204 B2 7,666,224 B2		Thornton et al. Vidlund et al.
	7,094,244 B2	8/2006		7,674,287 B2		Alferness et al.

US 11,026,791 B2

Page 3

(56)	References Cited	8,142,494 B2		Rahdert et al.
U.S	S. PATENT DOCUMENTS	8,147,542 B2 8,163,013 B2	4/2012	Maisano et al. Machold et al.
7 (02 210 D2	2/2010 34 4 1	8,172,856 B2 8,172,898 B2		Eigler et al. Alferness et al.
7,682,319 B2 7,682,369 B2		8,182,529 B2		Gordon et al.
7,695,510 B2	\mathcal{E}	8,187,207 B2		Machold et al.
7,695,512 B2		8,187,266 B2		Dickens et al.
7,699,892 B2		8,187,299 B2 8,187,323 B2		Goldfarb et al. Mortier et al.
7,704,277 B2 7,713,298 B2		8,202,315 B2		Hlavka et al.
7,717,954 B2		8,211,171 B2		Kim et al.
7,722,523 B2		8,216,230 B2		Hauck et al.
7,722,668 B2		8,216,256 B2 8,216,302 B2		Raschdorf et al. Wilson et al.
7,736,388 B2 7,744,609 B2		8,216,303 B2		
7,744,611 B2		8,226,709 B2		Groothuis et al.
7,753,858 B2		8,226,711 B2		Mortier et al.
7,753,922 B2		8,241,304 B2 8,241,351 B2		Bachman Cabiri
7,753,923 B2 7,753,924 B2		8,252,050 B2		Maisano et al.
7,758,595 B2		8,262,724 B2		Seguin et al.
7,758,596 B2		8,277,502 B2		Miller et al.
7,758,637 B2		8,287,555 B2 8,287,557 B2		Starksen et al. To et al.
7,758,639 B2 7,766,812 B2		8,303,608 B2		Goldfarb et al.
7,785,366 B2		8,303,622 B2		Alkhatib
7,794,496 B2		8,323,334 B2		Deem et al.
7,803,187 B2		8,328,798 B2 8,333,777 B2		Witzel et al. Schaller et al.
7,806,928 B2 7,811,296 B2		8,343,173 B2		Starksen et al.
7,811,236 B2		8,343,174 B2		Goldfarb et al.
7,828,841 B2		8,353,956 B2		Miller et al.
7,828,842 B2		8,357,195 B2 8,361,086 B2		Allen et al.
7,828,843 B2 7,837,728 B2		8,382,829 B1		Call et al.
7,837,729 B2		8,388,680 B2		Starksen et al.
, ,	2 12/2010 Alferness et al.	8,409,273 B2 8,425,504 B2		Thornton et al. Orton et al.
7,871,368 B2 7,871,433 B2	e e e e e e e e e e e e e e e e e e e	8,423,304 B2 8,439,971 B2		Reuter et al.
7,871,433 B2 7,883,538 B2		8,449,606 B2		Eliasen et al.
7,887,552 B2		8,454,656 B2		
7,887,582 B2		8,454,683 B2 8,460,370 B2		Rafiee et al. Zakay et al.
7,914,544 B2 7,922,762 B2	\mathcal{E} 3	8,460,371 B2		Hlavka et al.
7,927,370 B2		8,470,028 B2		Thornton et al.
7,931,684 B2	$\boldsymbol{\mathcal{E}}$	8,475,472 B2		Bachman Mayreat al
7,935,146 B2	\mathcal{L}_{i}	8,486,136 B2 8,500,761 B2		Maurer et al. Goldfarb et al.
7,938,827 B2 7,942,927 B2		8,500,800 B2		Maisano et al.
7,942,928 B2	-	8,506,623 B2		Wilson et al.
7,955,384 B2		8,506,624 B2 8,518,107 B2		Vidlund et al. Tsukashima et al
7,981,020 B2 7,981,123 B2		8,513,107 B2 8,523,881 B2		Cabiri et al.
7,981,125 B2 7,988,725 B2	\mathcal{L}	8,540,620 B2		Mortier et al.
7,988,726 B2		8,545,414 B2		Fitzgerald et al.
7,993,397 B2		8,545,553 B2 8,551,161 B2		Zipory et al.
7,998,151 B2 8,016,882 B2		8,579,967 B2		Webler et al.
8,029,565 B2		8,579,968 B1		Shannon et al.
8,043,368 B2		8,591,460 B2		Wilson et al.
8,052,592 B2		8,608,797 B2 8,632,585 B2		Gross et al. Seguin et al.
8,057,493 B2 8,062,313 B2	l 11/2011 Goldfarb et al. l 11/2011 Kimblad	8,641,727 B2		Ancora
8,062,358 B2		8,647,254 B2		Callas et al.
8,066,766 B2		8,663,322 B2		Keränen Maahald at al
8,070,746 B2		8,690,858 B2 8,690,939 B2		Machold et al. Miller et al.
8,070,805 B2 8,075,616 B2		8,709,074 B2		Solem et al.
8,092,363 B2		8,715,342 B2		Zipory et al.
8,092,525 B2		8,721,665 B2		Oz et al.
8,096,985 B2 8,100,964 B2	U 1	8,728,097 B1 8,734,467 B2		Sugimoto et al. Miller et al.
8,100,904 B2 8,109,984 B2	-	8,734,505 B2		St. Goar et al.
8,123,703 B2		8,740,918 B2		Seguin
8,128,691 B2		8,740,920 B2		Goldfarb et al.
8,133,239 B2		8,753,373 B2		Chau et al.
8,133,272 B2 8,142,493 B2		8,758,257 B2 8,758,393 B2		Cecere et al. Zentgraf
0,142,493 D2	. Spence et al.	0,730,393 D 2	0/2014	Zemgiai

(56)		Referen	ces Cited		9,198,757			Schroeder et al.
	U.S.	PATENT	DOCUMENTS		9,216,018 9,226,787 9,226,825	B2	1/2016	Sutherland et al. Merryman et al. Starksen et al.
8.758	3,432 B2	6/2014	Solem et al.		9,232,942			Seguin et al.
,	,292 B2		Allen et al.		9,232,998			Wilson et al.
8,777	,966 B2	7/2014	Dale et al.		9,237,886			Seguin et al.
,	3,016 B2		Janovsky et al.		9,254,141 9,259,218			Morris et al. Robinson
,	3,017 B2		Eliasen et al.		9,259,218			Boronyak et al.
,	1,482 B2 1,483 B2	7/2014	Rahdert et al. Navia		9,259,317			Wilson et al.
,	,394 B2		Miller et al.		9,265,608			Miller et al.
,	5,298 B2		Hernlund et al.		9,271,833			Kim et al.
8,795	5,352 B2		O'Beirne et al.		9,277,994			Miller et al.
,	3,368 B2		Maisano et al.		9,282,964 9,301,842			Cohen et al. Bielefeld
,	,570 B2 5,717 B2		Dumontelle et al. Khairkhahan et al.		9,314,242			Bachman
,	5,723 B2		Spence et al.		9,320,600			Nieminen et al.
,	2,213 B2		Gammie et al.		9,326,857			Cartledge et al.
8,858	3,622 B2	10/2014	Machold et al.		9,345,470		5/2016	
/	3,623 B2		Miller et al.		9,351,830 9,358,111			Gross et al. Spence et al.
/	1,822 B2		Spence et al.		9,358,111			Hlavka et al.
,	3,843 B2 3,844 B2		Khairkhanan et al. Eliasen et al.		9,370,424			Call et al.
,	/		Eliasen et al.		9,393,080	B2	7/2016	Zentgraf et al.
,	,461 B2		Traynor et al.		9,402,721			Buchbinder et al.
/	,494 B2	12/2014	Hammer et al.		9,408,695			Mathis et al.
,),322 B2		Mansi et al.		9,414,852 9,414,918			Gifford et al. Chau et al.
/	5,695 B2 5,696 B2		Gross et al. Cabiri et al.		9,414,921			Miller et al.
,	5,697 B2		Gross et al.		9,421,098	B2	8/2016	Gifford et al.
,	,348 B2		Solem et al.		9,421,099		8/2016	
,	3,283 B2		Zentgraf et al.		9,427,237 9,433,503			Oz et al. Tsukashima et al.
,),042 B2		Miller et al.		9,435,303			Tuval et al.
,),044 B2 5,177 B2		Hammer et al. Dell et al.		9,452,048			O'Beirne et al.
,	5,211 B2		Sugimoto		9,474,605			Rowe et al.
,	,285 B2	2/2015	Sugimoto et al.		9,474,606			Zipory et al.
,	,286 B2		Sugimoto et al.		9,474,608 9,492,276			Mathis et al. Lee et al.
/	5,406 B2 5,407 B2		Subramanian et al. Macoviak et al.		9,498,228			Dale et al.
,	,597 B2		Subramanian et al.		9,498,330		11/2016	Solem
,	3,335 B2		Robinson et al.		9,498,331			Chang et al.
,	3,393 B2		Rothstein		9,504,570 9,510,829			Hauser et al. Goldfarb et al.
,	1,445 B2 1,525 B2		Warnking et al. Nieminen et al.		9,510,829		12/2016	
/	9,923 B2		Spence et al.		9,510,946			Chau et al.
,	,925 B2		Chang et al.		9,510,948			Padala et al.
,	2,605 B2		Zakai et al.		9,526,613			Gross et al.
,	8,794 B2		Mortier et al.		9,526,614		12/2016 12/2016	Nieminen et al.
,	,463 B2		Rothstein et al. Adams et al.		9,532,874			Griffin et al.
,	,468 B2		Ketai et al.		9,545,305	B2	1/2017	Wilson et al.
9,011	,520 B2	4/2015	Miller et al.		9,561,104			Miller et al.
,	,530 B2		Reich et al.		9,561,105 9,572,666		2/2017	Basude et al.
,	,531 B2 1,221 B2		Rourke et al. Zentgraf et al.		9,572,667		2/2017	
,	,246 B2		Goldfarb et al.		9,579,200		2/2017	Lederman et al.
,	,187 B2		Sugimoto et al.		9,592,118			Khairkhahan et al.
,	,858 B2		Thornton et al.		9,592,122 9,597,184			Zipory et al. Machold et al.
,	5,710 B2		Dale et al.		9,597,184			Morris et al.
,	,658 B2 ,750 B2		Schaller et al. Cartledge et al.		9,610,161			Macoviak et al.
,	,718 B2		Keränen		9,610,162			Zipory et al.
,	,719 B2		Zipory et al.		9,610,163			Khairkhahan et al.
,	5,632 B2		Loulmet et al.		9,615,926 9,616,197			Lashinski et al. Serina et al.
,	5,653 B2 ,928 B2		Kovach Zlotnick et al.		9,622,862			Lashinski et al.
,	,939 B1		Call et al.		9,636,106		5/2017	Meier et al.
,	,137 B2		Subramanian et al.		9,636,107			Morales et al.
,	6,646 B2	11/2015			9,636,223			Khalil et al.
,	,896 B2 ,005 B1		Machold et al. Lashinski et al.		9,636,224 9,642,706			Zipory et al. Eidenschink
,	,003 B1 ,006 B2	-	Keranen		9,649,106			Nobles et al.
,	0,007 B2		Reich et al.		9,662,205			Eidenschink
9,180	,008 B2	11/2015	Yellin et al.		9,662,208			Padala et al.
			Zentgraf		9,662,209			Gross et al.
•	2,471 B2	11/2015	•	200	9,706,996			Nguyen et al.
9,192	.,4/2 B2	11/2015	Gross et al.	200	1/0005787	Al	0/2001	Oz et al.

(56)		Referen	ces Cited	2006/0229708			Powell et al.
	ΠC	DATENIT	DOCUMENTS	2006/0241745 2006/0241746		10/2006 10/2006	Solem Shaoulian et al.
	U.S.	FAILINI	DOCUMENTS	2006/0252984			Rahdert et al.
2002/018383	37 A1	12/2002	Streeter et al.	2006/0271174	A1	11/2006	Nieminen et al.
2003/010551			Fasol et al.	2006/0281968	A 1	12/2006	Duran et al.
2003/012034	40 A1	6/2003	Liska et al.	2006/0282161			Huynh et al.
2003/012034	41 A1		Shennib et al.	2006/0293698		12/2006	_
2004/001937			Hlavka et al.	2007/0027533 2007/0038293		2/2007 2/2007	St. Goar et al.
2004/002441			Downing St. Goar et al.	2007/0038297			Bobo et al.
2004/003038 2004/003944			St. Goar et al.	2007/0050022			Vidlund et al.
2004/004435			Martin et al.	2007/0055206	A 1	3/2007	To et al.
2004/010283			Cohn et al.	2007/0055368			Rhee et al.
2004/012798			Machold et al.	2007/0061010			Hauser et al.
2004/012798			Mortier et al.	2007/0066863 2007/0067027			Rafiee et al. Moaddeb et al.
2004/013306 2004/013324			McCarthy et al. Adams et al.	2007/007/3391			Bourang et al.
2004/01532-			Schroeder et al.	2007/0078297			Rafiee et al.
2004/015314			Seguin et al.	2007/0080188			Spence et al.
2004/015832	21 A1		Reuter et al.	2007/0100356			Lucatero et al.
2004/016261			Liska et al.	2007/0100439 2007/0112244			Cangialosi et al. McCarthy et al.
2004/016753			Kuehen et al.	2007/0112244			Spence et al.
2004/021024 2004/022065		10/2004	Mathis et al.	2007/0112121			Davidson
2004/022065			Nieminen et al.	2007/0118215			Moaddeb
2004/024322			Starksen et al.	2007/0129737			Goldfarb et al.
2004/025460	00 A1	12/2004	Zarbatany et al.	2007/0135913			Moaddeb et al.
2004/026039			Douk et al.	2007/0156235 2007/0173926			Rourke et al. Bobo et al.
2004/026708			McCarthy et al.	2007/0173920			Kapadia et al.
2005/002735 2005/003344			Rueter et al. Deem et al.	2007/0198038			Cohen et al.
2005/00334-			Taylor et al.	2007/0203391	A 1	8/2007	Bloom et al.
2005/007099			Spence	2007/0213758			Rourke et al.
2005/007100	00 A1	3/2005	Liddicoat et al.	2007/0232941			Rabinovich
2005/007572			Schroeder et al.	2007/0233238 2007/0244554			Huynh et al. Rafiee et al.
2005/010781			Morales et al.	2007/0244555			Rafiee et al.
2005/010781 2005/010787			Starksen et al. Realyvasquez et al.	2007/0244556			Rafiee et al.
2005/013744			Nieminen et al.	2007/0255396	A 1	11/2007	Douk et al.
2005/013745			Aronson et al.	2007/0265658			Nelson et al.
2005/014381			Realyvasquez	2007/0265702		11/2007	
2005/014881			Mortier et al.	2007/0270793 2007/0276437		11/2007 11/2007	Call et al.
2005/014901 2005/015981			Hauck et al. Filsoufi	2007/0276478			Marmureanu et al.
2005/013981			Solem et al.	2007/0282429	A 1		Hauser et al.
2005/018412			Hlavka et al.	2007/0293943		12/2007	•
2005/019769			Pai et al.	2008/0004597			Lattouf et al.
2005/019769			Pai et al.	2008/0015688 2008/0039935			Hill et al. Buch et al.
2005/019769 2005/020969			Pai et al. Mathis et al.	2008/0050347		2/2008	
2005/020903			Lederman	2008/0065205			Nguyen et al.
2005/021607			Starksen et al.	2008/0091059			Machold et al.
2005/022248	88 A1	10/2005	Chang et al.	2008/0091264			Machold et al.
2005/022248			Rahdert et al.	2008/0140188 2008/0140190			Rahdert et al. Macoviak et al.
2005/022842			Machold et al.	2008/0140190			St. Goar et al.
2005/024020 2005/026752			Shennib et al. Crockett et al.	2008/0177380			Starksen et al.
2005/026757			Cohn et al.	2008/0183283	A1	7/2008	Downing
2005/027313			To et al.	2008/0183285			Shaoulian et al.
2005/028877			Rhee et al.	2008/0195126		8/2008	
2005/028877			Shaoulian et al.	2008/0195200 2008/0200981			Vidlund et al. Shaoulian et al.
2006/001517 2006/002578			Moaddeb et al. Morales et al.	2008/0228032			Starksen et al.
2006/002376			Spence et al.	2008/0228201	A1	9/2008	Zarbatany et al.
2006/010069			Vidlund et al.	2008/0228265			Spence et al.
2006/010627			Machold et al.	2008/0228266			McNamara et al.
2006/010627			Machold et al.	2008/0228272 2008/0234701			Moaddeb et al. Morales et al.
2006/012263 2006/013605			To et al. Rourke et al.	2008/0234702			Morales et al.
2006/013003			Spence	2008/0234813		9/2008	
2006/011936			McCarthy et al.	2008/0243150			Starksen et al.
2006/016116			Nieminen et al.	2008/0249504	A 1		Lattouf et al.
2006/016747			Bloom et al.	2008/0249618			Huynh et al.
2006/017870		8/2006		2008/0319541		12/2008	
2006/018423			Solem et al.	2009/0043381			Macoviak et al.
2006/018424 2006/019501			Lichtenstein Mortier et al.	2009/0069885 2009/0076600		3/2009 3/2009	Rahdert et al.
2006/019301			Yang et al.	2009/00/0000			Shaolian et al.
_555,020020		J, 200				000	

(56)	Referen	ces Cited	2012/0185040 A1 2012/0197388 A1*		Rahdert et al. Khairkhahan A61B 17/0401
U.S.	PATENT	DOCUMENTS			623/2.11
			2012/0203072 A1		Lattouf et al.
2009/0118744 A1	5/2009	Wells et al.	2012/0209376 A1		Hauser et al.
2009/0118825 A1		Rourke et al.	2012/0209379 A1 2012/0215305 A1		Shaolian et al. Le et al.
2009/0149949 A1 2009/0177266 A1	6/2009	Quinn Powell et al.	2012/0213303 A1 2012/0221101 A1		Moaddeb et al.
2009/01/7200 A1 2009/0182418 A1		Solem et al.	2012/0271331 A1		To et al.
2009/0182419 A1		Bolling	2012/0310331 A1	12/2012	Eigler et al.
2009/0209950 A1		Starksen			Callas et al.
2009/0216322 A1		Le et al.	2013/0023985 A1*	1/2013	Khairkhahan A61L 27/042
2009/0222081 A1		Linder et al.	2013/0035757 A1	2/2013	Zenteraf et al. 623/2.38
2009/0228100 A1 2009/0287179 A1		Solem et al. Machold et al.	2013/0033737 A1 2013/0110230 A1		Zentgraf et al. Solem
2009/028/179 A1 2009/0306622 A1		Machold et al.	2013/0116236 711 2013/0116776 A1		Gross et al.
2009/0306685 A1	12/2009		2013/0123913 A1	5/2013	Kuehn
2009/0326648 A1		Machold et al.	2013/0131791 A1		Hlavka et al.
2010/0023056 A1		Johansson et al.	2013/0253639 A1		Alkhatib
2010/0023118 A1 2010/0030330 A1		Medlock et al. Bobo et al.	2013/0253641 A1 2013/0282059 A1		Lattouf Ketai et al.
2010/0036330 A1		Rourke et al.	2013/0202093 A1		Serina et al.
2010/0049213 A1		Serina et al.	2013/0304197 A1		Buchbinder et al.
2010/0094248 A1		Nguyen et al.	2014/0039607 A1		Kovach
2010/0121349 A1		Meier et al.	2014/0066693 A1		Goldfarb et al.
2010/0121433 A1 2010/0121435 A1		Bolling et al.	2014/0067048 A1 2014/0088693 A1		Chau et al. Seguin et al.
2010/0121433 A1 2010/0121437 A1		Subramanian et al. Subramanian et al.	2014/0033093 A1 2014/0135799 A1		Henderson
2010/0121137 A1		Subramanian et al.	2014/0148849 A1		Serina et al.
2010/0137887 A1	6/2010	Crockett et al.	2014/0155783 A1		Starksen et al.
2010/0152845 A1		Bloom et al.	2014/0172084 A1		Callas et al.
2010/0161044 A1 2010/0185172 A1		Chang et al. Fabro	2014/0188108 A1 2014/0207154 A1		Goodine et al. Bielefeld et al.
2010/0185172 A1 2010/0185273 A1		Solem et al.	2014/0207161 A1		Dell et al.
2010/0198056 A1		Fabro et al.	2014/0222138 A1	8/2014	Machold et al.
2010/0198192 A1		Serina et al.	2014/0228871 A1		Cohen et al.
2010/0198208 A1 2010/0210899 A1		Napp et al. Schankereli	2014/0243860 A1 2014/0243894 A1		Morris et al. Groothuis et al.
2010/0210399 A1 2010/0217283 A1		St. Goar et al.	2014/0243963 A1		Sheps et al.
2010/0249920 A1		Bolling et al.	2014/0257341 A1	9/2014	Eidenschink et al.
2010/0280602 A1	11/2010		2014/0275757 A1		Goodwin et al.
2010/0298929 A1		Thornton et al.	2014/0276648 A1 2014/0276971 A1		Hammer et al. Kovach
2010/0298930 A1 2010/0318184 A1	$\frac{11}{2010}$ $\frac{12}{2010}$		2014/02/09/1 A1		Sauer et al.
2010/0331971 A1		Keränen et al.			Sheps et al.
2011/0009957 A1			2014/0336756 A1		Lee et al.
2011/0011917 A1		Loulmet			Zentgraf Wilson et al.
2011/0015722 A1 2011/0022164 A1		Hauser et al. Quinn et al.			Morris et al.
2011/0022161 711 2011/0022166 A1		Dahlgren et al.			Sutherland et al.
2011/0060407 A1		Ketai et al.	2015/0018940 A1		Quill et al.
2011/0066234 A1		Gordon et al.	2015/0018941 A1		Lee et al.
2011/0092988 A1 2011/0093063 A1		Cohen et al. Schreck	2015/0032127 A1 2015/0038988 A1		Gammie et al. Tegels et al.
2011/0095005 A1 2011/0106106 A1		Meier et al.	2015/0045815 A1		Eidenschink
2011/0106117 A1		Mathis et al.	2015/0051697 A1	2/2015	Spence et al.
2011/0144743 A1		Lattouf	2015/0057682 A1		Kovach
2011/0172754 A1 2011/0207996 A1		Starksen et al. Starksen	2015/0066138 A1 2015/0073547 A1		Alexander et al. Eliasen et al.
2011/0207990 A1 2011/0213387 A1		Nguyen et al.	2015/0075347 AT 2015/0105804 A1		Dell et al.
2011/0224784 A1		Quinn	2015/0105855 A1	4/2015	Cabiri et al.
2011/0230961 A1		Langer et al.	2015/0112432 A1		Reich et al.
2011/0230962 A1		Moaddeb et al.	2015/0119981 A1 2015/0127091 A1		Khairkhahan et al. Cecere et al.
2011/0251684 A1 2011/0257740 A1		Rahdert et al. Shaoulian et al.	2015/012/091 A1 2015/0133999 A1		Robinson et al.
2011/0257741 A1		Moaddeb et al.	2015/0134050 A1		Solem et al.
		Duffy et al.	2015/0134053 A1		Morris et al.
2012/0010461 A1		Goldfarb et al.	2015/0134055 A1 2015/0134057 A1		Spence et al. Rourke et al.
2012/0041548 A1 2012/0053680 A1		Crabtree Bolling et al.	2015/0134057 A1 2015/0142105 A1		Bolling et al.
2012/0055060 AT 2012/0065464 A1		Ellis et al.	2015/0157459 A1		Macoviak et al.
2012/0095552 A1	4/2012	Spence et al.	2015/0164639 A1		Starksen et al.
2012/0101442 A1		Legaspi et al.	2015/0173740 A1		Sugimoto et al.
2012/0109288 A1 2012/0109289 A1		Bolling Bolling	2015/0173900 A1 2015/0182223 A1		Hauser et al. Ketai et al.
2012/0109289 A1 2012/0123532 A1		Mathis	2015/0182223 A1 2015/0223793 A1		Goldfarb et al.
2012/0136433 A1		Marmureanu et al.			Herman et al.
2012/0158020 A1		Crockett et al.	2015/0272734 A1		•
2012/0179184 A1	7/2012	Orlov	2015/0297212 A1	10/2015	Reich et al.

(56) References Cited

U.S. PATENT DOCUMENTS

11/2015 Zentgraf et al. 2015/0313713 A1 11/2015 Loulmet et al. 2015/0335430 A1 2015/0366556 A1 12/2015 Khairkhahan et al. 2015/0366666 A1 12/2015 Khairkhahan et al. 1/2016 Cabiri et al. 2016/0008132 A1 2016/0015515 A1 1/2016 Lashinski et al. 2016/0015517 A1 1/2016 Sutherland et al. 2016/0022419 A1 1/2016 Yellin et al. 2016/0038285 A1 2/2016 Glenn et al. 2016/0038286 A1 2/2016 Yellin et al. 2016/0058557 A1 3/2016 Reich et al. 2016/0067043 A1 3/2016 Machold et al. 4/2016 Foerster et al. 2016/0106420 A1 2016/0113762 A1 4/2016 Clague et al. 2016/0113767 A1 4/2016 Miller et al. 5/2016 Shaolian et al. 2016/0120642 A1 5/2016 Zentgraf et al. 2016/0143737 A1 6/2016 Wei 2016/0174979 A1 2016/0192925 A1 7/2016 Bachman 2016/0242909 A1 8/2016 Ketai et al. 9/2016 Chang et al. 2016/0262887 A1 2016/0287387 A1 10/2016 Wei 12/2016 Oz et al. 2016/0354082 A1 2016/0374812 A1 12/2016 Machold et al. 2017/0007405 A1 1/2017 Griffin et al. 2017/0020521 A1 1/2017 Krone et al. 2017/0042546 A1 2/2017 Goldfarb et al. 2/2017 Seguin 2017/0049455 A1 3/2017 Machold et al. 2017/0055969 A1 5/2017 Basude et al. 2017/0143330 A1 7/2017 Morris et al. 2017/0189013 A1 7/2017 Eidenschink 2017/0202554 A1

^{*} cited by examiner







FIG. 1










FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14

FLEXIBLE CANOPY VALVE REPAIR SYSTEMS AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/645,306, filed Mar. 20, 2018, which is hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

The present technology relates generally to a system for repairing a valve suffering from regurgitation, and associ- 15 ated systems and methods.

BACKGROUND OF THE INVENTION

The human heart is a four chambered, muscular organ that 20 provides blood circulation through the body during a cardiac cycle. The four main chambers include the right atrium and right ventricle which supplies the pulmonary circulation, and the left atrium and left ventricle which supplies oxygenated blood received from the lungs to the remaining 25 body. To ensure that blood flows in one direction through the heart, atrioventricular valves (tricuspid and mitral valves) are present between the junctions of the atrium and the ventricles, and semi-lunar valves (pulmonary valve and aortic valve) govern the exits of the ventricles leading to the lungs and the rest of the body. These valves contain leaflets or cusps that open and shut in response to blood pressure changes caused by the contraction and relaxation of the heart chambers. The leaflets move apart from each other to open and allow blood to flow downstream of the valve, and coapt 35 to close and prevent backflow or regurgitation in an upstream manner.

The mitral valve, also known as the bicuspid or left atrioventricular valve, is a dual flap valve located between the left atrium and the left ventricle. The mitral valve serves 40 to direct oxygenated blood from the lungs through the left side of the heart and into the aorta for distribution to the body. As with other valves of the heart, the mitral valve is a passive structure in that does not itself expend any energy and does not perform any active contractile function. The 45 mitral valve includes two moveable leaflets, an anterior leaflet and a posterior leaflet, that each open and close in response to differential pressures on either side of the valve. Ideally, the leaflets move apart from each other when the valve is in an open configuration, and meet or "coapt" when 50 the valve is in a closed configuration.

Diseases associated with heart valves, such as those caused by damage or a defect, can include stenosis and valvular insufficiency or regurgitation. These diseases can occur individually or concomitantly in the same valve. 55 Valvular insufficiency or regurgitation occurs when the valve does not close completely, allowing blood to flow backwards, thereby causing the heart to be less efficient. A diseased or damaged valve, which can be congenital, agerelated, drug-induced, or in some instances, caused by 60 infection, can result in an enlarged, thickened heart that loses elasticity and efficiency. Some symptoms of heart valve diseases can include weakness, shortness of breath, dizziness, fainting, palpitations, anemia and edema, and blood clots which can increase the likelihood of stroke or pulmo- 65 nary embolism. Symptoms can often be severe enough to be debilitating and/or life threatening.

2

In particular, a large portion or percentage of degenerative regurgitation in a mitral valve is caused by a prolapsed posterior mitral leaflet. This can be caused by weakening or separation of the chordae attached to the posterior leaflet. In such cases, when the mitral valve is in the closed configuration, the posterior mitral leaflet billows or bulges like a sail or a parachute into the left atrium, causing the posterior leaflet to not fully coapt with the anterior mitral leaflet.

Currently, treatment options for the repair of a prolapsing leaflet includes re-sectioning of the prolapsed tissue, chordae repair, foldoplasty, annuloplasty, placement of a new valve, or attachment of a clip to couple a free end of the prolapsing leaflet to a free end of a non-prolapsing leaflet. However, these solutions have significant drawbacks in terms of efficacy, safety or likelihood of complications, invasiveness, reduction in the cross-sectional area for blood flow through the valve, and the availability of the valve for future treatments.

Accordingly, there is a need for systems that can repair a valve suffering from regurgitation due to a prolapsing leaflet more easily, with greater efficacy and fewer complications. Further, there is a need for systems that can repair a valve suffering from regurgitation due to a prolapsing leaflet while leaving the valve available for future treatments.

BRIEF SUMMARY OF THE INVENTION

Embodiments hereof are directed to a system for treating a valvular regurgitation in a heart valve. The system includes a flexible canopy and an elongated tether. A proximal end of the elongated tether is attached to a distal end of the flexible canopy. The flexible canopy includes a first surface and a second surface opposite the first surface. The elongated tether is configured to be placed under tension in situ and includes an inelastic portion and an elastic portion that is at least as long as the inelastic portion. When the system is in a deployed configuration, a proximal end of the flexible canopy is anchored to an annulus of a heart valve and a distal end of the elongated tether is anchored to tissue of a ventricle such that the first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve. The elongated tether is placed under tension such that the system is configured to prevent the first leaflet of the heart valve from prolapsing, and to permit a portion of the second surface of the flexible canopy to coapt with at least an opposing mating portion of a second leaflet of the heart valve.

In another embodiment hereof, the system includes a flexible canopy and an elongated tether. A proximal end of the elongated tether is attached to a distal end of the flexible canopy. The flexible canopy includes a first surface and a second surface opposite the first surface. The flexible canopy is unsupported and does not include a frame attached thereto. The elongated tether is configured to be placed under tension in situ and includes an inelastic portion and an elastic portion. When the system is in a deployed configuration, a proximal end of the flexible canopy is anchored to an annulus of a heart valve and a distal end of the elongated tether is anchored to tissue of a ventricle such that the first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve. The elongated tether is placed under tension such that the system is configured to prevent the first leaflet of the heart valve from prolapsing, and to permit a portion of the second surface of the flexible canopy to coapt with at least an opposing mating portion of a second leaflet of the heart valve.

Embodiments hereof are further directed to a method of treating a valvular regurgitation. The method includes percutaneously delivering a system in a delivery configuration to a heart valve. The system includes a flexible canopy and an elongated tether attached to a distal end of the flexible 5 canopy. The flexible canopy is unsupported and does not include a frame coupled thereto and the elongated tether includes an inelastic portion and an elastic portion that is at least as long as the inelastic portion. At least one proximal anchor is embedded into an annulus of the heart valve. A proximal end of the flexible canopy is coupled to the at least one proximal anchor. A distal anchor is embedded into a ventricle adjacent to the heart valve. A distal end of the force is applied on the flexible canopy such that a first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve. The heart valve is checked for regurgitation. The tension force on the flexible canopy is adjusted to minimize valvular regurgitation.

BRIEF DESCRIPTION OF DRAWINGS

The foregoing and other features and aspects of the present technology can be better understood from the following description of embodiments and as illustrated in the accompanying drawings. The accompanying drawings, which are incorporated herein and form a part of the specification, further serve to illustrate the principles of the present technology. The components in the drawings are not 30 necessarily to scale.

- FIG. 1 is a schematic sectional illustration of a mammalian heart having native valve structures.
- FIG. 2A is a schematic sectional illustration of a left ventricle of a mammalian heart showing anatomical struc- 35 tures and a native mitral valve.
- FIG. 2B is a schematic sectional illustration of the left ventricle of a heart having a prolapsed mitral valve in which the leaflets do not sufficiently coapt and which is suitable for repair with a system in accordance with embodiments 40 hereof.
- FIG. 2C is a schematic sectional illustration of the left ventricle of FIG. 2B as viewed from a different angle.
- FIG. 2D is a top view illustration of the prolapsed mitral valve of FIG. 2B, wherein the mitral valve is in an open 45 configuration.
- FIG. 3A is a perspective illustration of a system for treating heart valvular regurgitation in accordance with an embodiment hereof.
- FIG. 3B is a perspective illustration of the system of FIG. 50 3A and an anterior leaflet of a native mitral valve.
- FIG. 4 is a schematic sectional illustration of a heart, wherein the system of FIG. 3A is implanted within the heart in a deployed configuration and a native mitral valve of the heart is in the open configuration.
- FIG. 5 is a schematic sectional illustration of the heart, wherein the system of FIG. 3A is implanted within the heart in a deployed configuration and the native mitral valve of the heart in a closed configuration.
- 5, wherein the mitral valve is in the closed configuration.
- FIG. 7A is a perspective illustration of a system for treating heart valvular regurgitation in accordance with another embodiment hereof.
- FIG. 7B is a perspective illustration of a system for 65 treating heart valvular regurgitation in accordance with yet another embodiment hereof.

- FIG. 8 is a sectional cut-away illustration of a heart illustrating a method step of using the system of FIG. 3A to repair a prolapsed posterior leaflet of a native mitral valve using a transseptal approach in accordance with an embodiment hereof, wherein the system of FIG. 3A is shown in the delivery configuration within a delivery catheter positioned within the left atrium of the heart.
- FIG. 9 is a sectional cut-away illustration of the heart illustrating a method step of using the system of FIG. 3A to 10 repair the prolapsed posterior leaflet of the native mitral valve, wherein a plurality of proximal anchors is deployed to engage tissue at the annulus of the native mitral valve.
- FIG. 10 is a sectional cut-away illustration of the heart illustrating a method step of using the system of FIG. 3A to elongated tether is coupled to the distal anchor. A tension 15 repair the prolapsed posterior leaflet of the native mitral valve, wherein a proximal end of a flexible canopy of the system is coupled to the plurality of proximal anchors at the annulus of the native mitral valve.
 - FIG. 11 is a sectional cut-away illustration of the heart 20 illustrating a method step of using the system of FIG. **3A** to repair the prolapsed posterior leaflet of the native mitral valve, wherein a distal anchor is deployed to engage tissue in a left ventricle of the heart.
 - FIG. 12 is a sectional cut-away illustration of the heart illustrating a method step of using the system of FIG. 3A to repair the prolapsed posterior leaflet of the native mitral valve, wherein a distal end of an elongated tether of the system is coupled to the distal anchor in the left ventricle.
 - FIG. 13 is a sectional cut-away illustration of the heart illustrating a method step of using the system of FIG. 3A to repair the prolapsed posterior leaflet of the native mitral valve, wherein a tension of the elongated member is applied such that the flexible canopy overlays the posterior leaflet of the native mitral valve.
 - FIG. 14 is a sectional cut-away illustration of the heart illustrating a method step of using the system of FIG. 3A to repair the prolapsed posterior leaflet of the mitral valve, wherein the tension of the elongated tether is adjusted to minimize regurgitation at the mitral valve.

DETAILED DESCRIPTION OF THE INVENTION

Specific embodiments of the present invention are now described with reference to the figures, wherein like reference numbers indicate identical or functionally similar elements. The terms "distal" and "proximal", when used in the following description to refer to a delivery device, delivery system, or delivery catheter are with respect to a position or direction relative to the treating clinician. Thus, "distal" and "distally" refer to positions distant from, or in a direction away from the treating clinician, and the terms "proximal" and "proximally" refer to positions near, or in a direction toward the clinician. The terms "distal" and "proximal", 55 when used in the following description to refer to a system or a device to be implanted into a vessel, such as a system for treating heart valvular regurgitation, are used with reference to the direction of blood flow. Thus, "distal" and "distally" refer to positions in a downstream direction with FIG. 6 is a top view illustration of the mitral valve of FIG. 60 respect to the direction of blood flow, and the terms "proximal" and "proximally" refer to positions in an upstream direction with respect to the direction of blood flow.

> The following detailed description is merely exemplary in nature and is not intended to limit the present technology or the application and uses of the present technology. Although the description of embodiments hereof is in the context of treatment of heart valvular regurgitation and particularly in

the context of treatment of regurgitation of the mitral valve, the present technology may also be used in any other body passageways where it is deemed useful. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, back- 5 ground, brief summary or the following detailed description.

FIGS. 1-2D will now be described to provide contextual information on valve regurgitation. FIG. 1 is a schematic sectional illustration of a mammalian heart HE that depicts the four heart chambers (right atrium RA, right ventricle RV, left atrium LA, left ventricle LV) and native valve structures (tricuspid valve TV, mitral valve MV, pulmonary valve PV, aortic valve AV). FIG. 2A is a schematic sectional illustration of a left ventricle LV of a mammalian heart HE showing anatomical structures and a native mitral valve MV. Referring to FIGS. 1 and 2A together, the heart HE comprises the left atrium LA that receives oxygenated blood from the lungs via the pulmonary veins. The left atrium LA pumps the oxygenated blood through the mitral valve MV and into the 20 left ventricle LV during ventricular diastole. The left ventricle LV contracts during systole and blood flows outwardly through the aortic valve AV, into the aorta and to the remainder of the body.

In a healthy heart, the mitral valve MV includes an open 25 configuration and a closed configuration. When the mitral valve MV is in the open configuration, an anterior leaflet AL and a posterior leaflet PL do not coapt, permitting blood to flow from the right atrium RA to the left ventricle LV. When the mitral valve is in the closed configuration, as shown in 30 FIG. 2A, the anterior and posterior leaflets AL, PL of the native mitral valve MV meet evenly at the free edges or "coapt" to close and prevent back flow of blood into the left atrium LA during contraction of the left ventricle LV. The tissue of the anterior and posterior leaflets AL, PL attach to 35 the surrounding heart structure via a dense fibrous ring of connective tissue called an annulus AN which is distinct from both the tissue of the anterior and posterior leaflets AL, PL as well as the adjoining muscular tissue of the heart wall. In general, the connective tissue at the annulus AN is more 40 fibrous, tougher and stronger than leaflet tissue. The flexible tissue of the anterior and posterior leaflets AL, PL of the native mitral valve MV are connected to papillary muscles PM, which extend upwardly from the lower wall of the left ventricle LV and the interventricular septum IVS, via 45 branching tendons called chordae tendinae CT.

In a heart HE having a mitral valve MV experiencing valvular regurgitation due to a prolapsing first or posterior leaflet PL and a second or anterior leaflet AL, the respective edges of the posterior leaflet PL and the anterior leaflet AL do not sufficiently coapt or meet, as shown in FIGS. 2B-2D and leakage from the left ventricle LV into the left atrium LA will occur through a gap GP. Several structural defects can cause the mitral leaflets LF to prolapse, and subsequent regurgitation to occur, including ruptured chordae tendinae 55 CT, impairment of papillary muscles PM (e.g., due to ischemic heart disease), and enlargement of the heart and/or mitral valve annulus AN (e.g., cardiomyopathy).

Embodiments of systems and associated methods in accordance with the present technology are described with 60 reference to FIGS. 3A-14. It will be appreciated that specific elements, substructures, uses, advantages, and/or other aspects of the embodiments described herein and with reference to FIGS. 3A-14 can be suitably interchanged, accordance with additional embodiments of the present technology.

Provided herein are systems and methods suitable for repairing a prolapsing leaflet of a heart valve to reduce or eliminate valvular regurgitation. More specifically, in embodiments hereof, a flexible canopy of the system is placed over an existing native leaflet of the heart valve and tensioned with an elongated tether to prevent leaflet prolapse and subsequent regurgitation resulting from the prolapsing leaflet. The system is adjustable via the elongated tether to set the system to minimize or eliminate valvular regurgitation. Further, the system may be readjusted during the initial procedure or in a subsequent procedure or procedures to account for changes in the native anatomy over time. The systems described herein do not reduce or alter the crosssectional area of the native mitral valve and thus reduced blood flow through the heart valve is avoided and easy access to the heart valve is still permitted for future therapies and treatments.

Turning now to FIG. 3A, FIG. 3A is a perspective view of a system 100 for treating valvular regurgitation in a heart valve due to a prolapsing leaflet and configured in accordance with an embodiment hereof. The system 100 includes a flexible canopy 102 and an elongated tether 104. Further, the system 100 includes a delivery configuration, wherein the system is compressed for percutaneous delivery within a delivery catheter to a desired treatment location, and a deployed configuration, which is shown in FIG. 3A. When the system 100 is in the delivery configuration, the flexible canopy 102 can be folded, rolled, or otherwise compressed. The method of compressing the flexible canopy 102 is selected based upon a variety of characteristics including, but not limited to the order or sequence of anchor fixation or deployment.

As shown in FIG. 3A, the flexible canopy 102 is formed of a flexible material and includes a proximal end 106, a distal end 108 opposite the proximal end 106, an underside or first surface 114 and a top or second surface 116 opposite the first surface 114. The flexible canopy 102 may be formed of materials which will bond to the prolapsing leaflet via growth such as, but not limited to Dacron®, pericardial tissue, or other suitable materials. The proximal end 106 of the flexible canopy 102 is configured to be anchored in situ at or on an annulus of the heart valve. As used herein, "at or on" an annulus means at or on a level of a plane of the annulus of the native heart valve, including disposition at or on a level of an upper surface of the annulus or other superior levels of the valve. Further, when the system 100 is in the deployed configuration, the flexible canopy 102 is configured to overlay an underlying or concealed portion of a prolapsing leaflet of the native heart valve such that the first surface 114 abuts against or contacts the underlying portion of the prolapsing leaflet, as described in more detail below. The flexible nature of the flexible canopy 102 permits the flexible canopy 102 to conform to the shape of the native prolapsing leaflet as best shown in FIG. 3B. FIG. 3B shows the system 100 with the flexible canopy 102 thereof overlaying and conforming to a native posterior leaflet PL, with the flexible canopy 102 coapting with a native anterior leaflet AL of a native heart valve. As used herein, the term "conform" means that the flexible canopy 102 assumes the same shape, outline, or contour of the underlying anatomy of the native prolapsing leaflet such that the flexible canopy 102 maintains consistent and close contact with the native prolapsing leaflet adjacent thereto. Thus, while the flexible canopy 102 of FIG. 3A is shown with a particular shape, this substituted or otherwise configured with one another in 65 is by way of example and not limitation, and it will be understood that the flexible canopy 102 assumes or conforms to the shape of the native prolapsing leaflet. Such

conformability is required in order for the system 100, and more particularly the flexible canopy 102 to prevent the native leaflet from prolapsing when the system 100 is in the deployed configuration as described in greater detail below. Over time, due to the material of the flexible canopy 102, the first surface 114 of the flexible canopy 102 bonds or fuses to the underlying first surface of the prolapsing leaflet.

In the embodiment of FIG. 3A, the first surface 114 of the flexible canopy 102 includes a plurality of micro-tines or micro-barbs 110 configured to aid in coupling the first surface 114 of the flexible canopy 102 to the underlying first surface of the native prolapsing leaflet. While shown in FIG. 3A with three (3) micro-barbs 110, this is by way of example and not limitation and more or fewer micro-barbs 110 may be used. In an embodiment, the micro-barbs 110 may have a diameter in a range of between about 0.005 inches and about 0.010 inches, and the length of the micro-barbs 110 may be in a range of between about 0.010 inches and about 0.100 inches. The micro-barbs 110 may be shaped to embed 20 into an adjacent surface such as, but not limited to, a wedged shape where the tip of the wedge comes in contact with the adjacent surface. In another embodiment, the micro-barbs 110 may be a series of metallic wires.

In the embodiment depicted in FIGS. 3A and 3B, the 25 flexible canopy 102 is unsupported. Stated another way, in the embodiment depicted in FIGS. 3A and 3B, the flexible canopy 102 does not include a support frame and consists only of the flexible material that has the first surface 114 and the opposing second surface 116. As used herein, "unsupported" means that the flexible canopy has no radial or longitudinal support along its length and is not attached to a scaffold or frame structure. Due to the unsupported nature thereof, the flexible canopy 102 is permitted to conform to the underlying leaflet structure and further is non-traumatic 35 to the surrounding native anatomy.

The size and perimeter of the flexible canopy 102 may be selected based upon the desired amount of leaflet coverage, the shape of the native anatomy, and/or desired anchoring positions. As best shown in FIG. 3B, in an embodiment 40 hereof, the flexible canopy 102 has an oblong shape and is configured to overlay the prolapsing leaflet of the native heart valve such that the first surface 114 of the flexible canopy is in contact with substantially the entire underlying surface (i.e., at least 90%) of the prolapsing leaflet of the 45 native heart valve. In another embodiment hereof, the flexible canopy 102 is configured to overlay the prolapsing leaflet of the native heart valve such that the first surface 114 of the flexible canopy is in contact with between forty and ninety percent (40-90%) of the underlying surface of the 50 prolapsing leaflet of the native heart valve. In addition, while the flexible canopy 102 of FIGS. 3A and 3B is shown with a particular length that extends distally a particular distance, this is by way of example and not limitation, and it will be understood that other lengths that are suitable to treat 55 valvular regurgitation may be used. More particularly, as best shown in FIG. 3B, in an embodiment the flexible canopy 102 extends distally beyond a distal end of the native posterior leaflet PL. However, in an alternative embodiment, the flexible canopy 102 does not extend beyond a prolapsing 60 portion of the posterior leaflet PL. It will be understood that the shape and size of the flexible canopy 102 may assume any and all possible permutations including, but not limited to the flexible canopy 102 spanning most of the native prolapsing leaflet, spanning just past the prolapsing portion 65 of the native prolapsing leaflet or any other configurations suitable for the purposes described herein.

8

The elongated tether 104 will now be described in more detail with reference to FIG. 3A. The elongated tether 104 has a first length L1 extending from a proximal end 120 thereof, which is attached to the distal end 108 of the flexible canopy 102, to a distal end 122 thereof. The proximal end 120 of the elongated tether 104 may be coupled to the distal end 108 of the flexible canopy 102 by methods including but not limited to adhesives, tying, sutures, mechanical devices, fusing, or any other method suitable for the purposes 10 described herein. The elongated tether **104** includes an elastic portion 124 coupled to an inelastic portion 126. The elastic portion 124 is an elongate member having elastic qualities. As used herein, "elastic" means that the elongate member returns or is able to resume its original length or shape after distortion. The elastic portion 124 may be formed of elastic materials such as, but not limited to prosthetic chordae materials such as silicone, gore, Goretex®, or any other suitable material. When the system 100 is in the deployed configuration in situ, the elastic portion **124** is configured to allow for dynamic movement of the flexible canopy 102. The inelastic portion 126 is an elongate member having inelastic qualities. As used herein, "inelastic" means that the elongate member 126 is not elastic and cannot be stretched. The inelastic portion 126 may be formed of inelastic materials such as, but not limited to a monofilament or plastic suture materials such as polypropylene, metal alloys such as stainless steel, titanium, or nickel-titanium alloys (i.e. NITINOL), or any other suitable material.

The elongated tether **104** is continuous or stated another way, the elastic portion 124 and the inelastic portion 126 collectively form the elongated tether 104. The elastic portion 124 includes a proximal end 128 and a distal end 130, while the inelastic portion 126 includes a proximal end 132 and a distal end 134. In the embodiment of FIGS. 3-6, the elastic portion 124 is disposed proximal of the inelastic portion 126. More specifically, the proximal end 128 of the elastic portion 124 is coupled to the distal end 108 of the flexible canopy 102 and the distal end 130 of the elastic portion 124 is coupled to the proximal end 132 of the inelastic portion 126. The proximal end 132 of the inelastic portion 126 may be coupled to the distal end 130 of the elastic portion 124 by methods including, but not limited to adhesives, tying, sutures, mechanical devices, fusing, or any other method suitable for the purposes described herein. The ratio of the elastic portion 124 to the inelastic portion 126 with reference to the first length L1 of the elongated tether 104 is selected based on a variety of characteristics including, but not limited to the native valve location, the native anatomy, and the characteristics and geometry of the system 100. In an embodiment hereof, as shown in FIGS. 3A and 3B, the elastic portion 124 is longer than the inelastic portion **126** to ensure that dynamic movement of the flexible canopy 102 is permitted in situ. For example, the ratio of the elastic portion 124 to the inelastic portion 126 of the elongated tether **104** may be 50/50, 60/40, 70/30, or other ratio found suitable for repairing valvular regurgitation.

The distal end 122 of the elongated tether 104 is coupled to a distal anchor (not shown in FIG. 3A) which is anchored in a ventricle adjacent the prolapsing valve. The elongated tether 104 is configured to be placed into tension when the system 100 is in the deployed configuration and implanted in situ, as described in more detail below. When placed into tension, the elongated tether 104 pulls on the distal end 108 of the flexible canopy 102 in a distal direction as indicated by a directional arrow 150. Stated another way, when the elongated tether 104 is placed into tension during implan-

tation, the elongated tether 104 places the flexible canopy **102** into tension. Further, the tension on the elongated tether 104 is configured to be adjustable in situ to adjust or tune the curvature of the flexible canopy 102 and/or the angle at which the flexible canopy 102 coapts with the non-prolaps- 5 ing leaflet or leaflets of the heart valve to minimize or reduce regurgitation. When the tension applied to the elongated tether 104 is increased, the elastic portion 124 of the elongated tether 104 stretches or elongates and the first length L1 of the elongated tether 104 relatively increases. 10 Conversely, when the tension applied to the elongated tether 104 is decreased, the elastic portion 124 of the elongated tether 104 shortens and the first length L1 of the elongated tether 104 relatively decreases. Devices and methods for placing the elongated tether 104 into tension will be dis- 15 cussed in more detail with respect to FIG. 4 below.

The interaction of the components of the system 100 will now be described with reference to FIGS. 4-6. FIGS. 4 and 5 are schematic sectional illustrations of the system 100 in a deployed configuration implanted within a heart HE, with 20 FIG. 4 illustrating a native mitral valve MV of the heart in an open configuration and FIG. 5 illustrating the native mitral valve MV of the heart HE in a closed configuration. FIG. 6 is a top view illustration of the native mitral valve MV of the heart HE in the closed configuration. Within 25 FIGS. **4-6**, the direction of blood flow is indicated by arrows BF. The system 100 is configured to repair a prolapsing posterior leaflet PL of the mitral valve MV. More particularly, when the system 100 is in the deployed configuration and implanted within the heart HE, the proximal end 106 of 30 the flexible canopy 102 is anchored or coupled to an annulus AN of the mitral valve MV by at least one proximal anchor **136**. The first surface **114** of the flexible canopy **102** overlays and is in contact with an underlying first surface of the first or posterior leaflet PL of the mitral valve MV. The elongated 35 tether 104 extends from the distal end 108 of the flexible canopy 102 to a distal anchor 138 in the left ventricle LV.

The proximal and distal anchors 136, 138 may be of any anchor suitable for embedding into the tissue of the annulus AN and the left ventricle LV, respectively, including but 40 limited to helical screws or anchors, barbs, or clips. In the embodiment illustrated in FIGS. 4 and 5, each of the proximal anchors 136 and the distal anchor 138 are shown as helical screws or anchors. Each helical anchor 136, 138 is rotatable by a corresponding releasable shaft of a delivery 45 catheter to embed the respective helical anchor in myocardial tissue. For example, and not by way of limitation, each of the proximal and distal anchors 136, 138 may be an anchor as described in U.S. Pat. No. 3,974,834 to Kane or U.S. Pat. No. 4,046,151 to Rose, each of which is assigned 50 to the same assignee of the present invention and each of which is hereby incorporated by reference in its entirety herein. While described herein as helical anchors 136, 138, this is by way of example and not limitation and the shape of the proximal and distal anchors 136, 138 may have other 55 shapes and other methods for delivery. For example, and not by way of limitation, the proximal and/or distal anchors 136, 138 may be an anchor as described in U.S. Pat. No. 4,341,226 to Peters or U.S. Pat. No. 9,775,982 to Grubac et al., each of which is assigned to the same assignee of the 60 present invention and each of which is hereby incorporated by reference in its entirety herein.

As described above, when the system 100 is in the deployed configuration and implanted in situ as shown in FIG. 4, the elongated tether 104 is placed into tension in 65 order to properly position the flexible canopy 102 to overlay the underlying first surface of the first or posterior leaflet PL

10

of the mitral valve MV. In an embodiment hereof, the distal end 122 of the elongated tether 104 is pre-attached to the distal anchor 138 and the elongated tether 104 is placed into tension by attaching the distal anchor 138 to the left ventricle LV in such a way that provides tension to the elongated tether 104. More particularly, tension is provided to the elongated tether 104 by varying the amount that the distal anchor 138 is advanced or embedded into a wall of the left ventricle LV. For example, when the distal anchor 138 is a helical screw as shown, the distal anchor 138 may be screwed into the wall of the left ventricle LV a greater amount or distance to increase the tension applied to the elongated tether 104. Conversely, the distal anchor 138 may be unscrewed to decrease the tension applied to the elongated tether 104, if desired. In another embodiment hereof, the distal end **122** of the elongated tether **104** is pre-attached to the distal anchor 138, and the elongated tether 104 is placed into tension by varying the angle at which the elongated tether 104 extends from the flexible canopy 102. More particularly, the location of the distal anchor 138 may be moved to increase or decrease the angle at which the elongated tether 104 extends from the flexible canopy 102. For example, the location of the distal anchor 138 may be moved towards the apex AP of the left ventricle LV to increase the tension applied to the elongated tether 104. Conversely, the location of the distal anchor 138 may be moved towards the interventricular septum IVS of the left ventricle LV to decrease the tension applied to the elongated tether 104.

In another embodiment hereof, the elongated tether 104 is configured to be placed into tension via a tensioning device or tensioner (now shown). For example, a tensioning device as described in U.S. Pat. No. 9,452,048 to O'Bierne et al., assigned to the same assignee of the present invention and which is hereby incorporated by reference in its entirety herein, may be modified and utilized as a tensioning device or tensioner. For example, the elongated tether 104 may initially be slidably coupled to the distal anchor 138 via an integral loop of the elongated tether 104 such that a free end of the elongated tether 104 extends proximally through a delivery catheter and is accessible to the physician. After the distal anchor 138 is secured to the wall of the ventricle, the physician may pull on the accessible free end of the elongated tether 104 to effectively decrease the first length L1 of the elongated tether 104 in situ and further effectively increase the tension placed on the elongated tether 104. Conversely, the physician may release or push the free end of the elongated tether 104 to effectively increase the first length L1 of the elongated tether 104 in situ and further effectively decrease the tension placed the elongated tether 104. Once the tension is optimized, a locking mechanism as described in U.S. Pat. No. 9,452,048 to O'Bierne et al., previously incorporated by reference above, may be slid or advanced over the free end of the elongated tether 104 and through the delivery catheter until the locking mechanism abuts against the distal anchor 138 and thereby secures the position of the elongated tether 104 being placed under the desired amount of tension. Any excess length of the elongated tether 104, i.e., the length of tether extending from the locking mechanism to the free end extending proximally back to the physician, may be cut and removed from the patient. A tensioning device has been described herein by way of example and not limitation. It will be understood that the tensioning device may be any suitable device configured to permit the elongated tether 104 to be placed into tension, and more specifically to adjust or change the first length L1

of the elongated tether 104 to increase or decrease the amount of tension placed onto the elongated tether 104 as described above.

Regardless of which method or device is used to place the elongated tether 104 into tension, the first length L1 of the 5 elongated tether 104 is varied during adjustment of the tension placed on the elongated tether 104. Accordingly, when the first length L1 of the elongated tether 104 is reduced to increase the tension placed on the elongated tether 104, the elastic portion 124 thereof is stretched. Because of the desire of the elastic portion **124** to return to its resting shape or length, the elastic portion 124 is placed into spring tension. This spring tension is transferred to adjacent coupled components as a tension force. More 15 canopy 202 and the frame 242 further generally follows the precisely, the spring tension pulls on the proximal end 132 of the inelastic portion 126 and is transferred through the inelastic portion 126 to the distal end 122 of the elongated tether 104 anchored to the left ventricle LV by the distal anchor 138 with a first tension force represented by a 20 directional arrow TF1 illustrated in FIG. 5. Further, the spring tension pulls on the distal end 108 of the flexible canopy 102 and is transferred through the flexible canopy 102 to the proximal end 106 of the flexible canopy 102 anchored at the annulus AN by the at least one proximal 25 anchor 136 with a second tension force represented by a directional arrow TF2 illustrated in FIG. 5. For the purposes described herein, the distal anchor 138 and the at least one proximal anchor 136 are stationary relative to the system **100**. It will be understood that the first and second tension 30 forces TF1 and TF2 are equal and opposite. The distal end 108 of the flexible canopy 102 is pulled in the direction of the arrow TF2 with sufficient tension force that the flexible canopy 102, or more precisely the first surface 114 thereof is placed into contact with the underlying first surface of the 35 posterior leaflet PL, and thereby prevents the posterior leaflet PL from prolapsing. Further, the tension force on the flexible canopy 102 may be adjusted to optimize coaptation of the flexible canopy 102 with the second leaflet of the heart valve, and to minimize valvular regurgitation. Stated another 40 way, the tension force on the elongated tether 104 is adjustable to maximize coaptation of a portion of the second surface 116 of the flexible canopy 102 with an opposing mating portion of an anterior leaflet AL of the mitral valve MV, and to minimize or eliminate regurgitation at the mitral 45 valve MV.

While shown with three proximal anchors 136 in specific locations in FIG. 6, this is by way of example and not limitation. It will be understood that more or fewer proximal anchors 136 may be used, and that the proximal anchor(s) 50 136 may be disposed at other locations. Further, while the distal anchor **138** is shown in FIG. **5** disposed at the apex AP of the left ventricle LV, this too is by way of example and not limitation. The distal anchor 138 may be disposed at any location within the left ventricle LV to optimize an angle 55 between the coapting surfaces of the flexible canopy 102 and the anterior leaflet AL. For example, the distal anchor 138 may be disposed at any location within the left ventricle LV including, but not limited to the apex AP, the ventricle wall, the interventricular septum IVS, or the papillary muscle PM. 60

FIG. 7A is a perspective view of a system 200 for treating regurgitation of a heart valve due to a prolapsing leaflet and configured in accordance with another embodiment hereof. The system 200 includes a flexible canopy 202 and an elongated tether 204, the elongated tether 204 including an 65 elastic portion 224 and an inelastic portion 226. In the embodiment in FIG. 7A, the flexible canopy 202 includes a

frame 242 and the elongated tether 204 has an alternative configuration than the elongated tether 104 described above.

As shown in FIG. 7A, the flexible canopy 202 is formed of a flexible material and is similar to the flexible canopy 102 previously described. Therefore, similar details of the configuration and materials of the flexible canopy 202 will not be repeated. However, the flexible canopy 202 is supported by a frame 242 coupled to the material of the flexible canopy 202. The frame 242 is disposed at a proximal portion 10 **248** of the flexible canopy **202**. In the embodiment of FIG. 7A, the frame 242 has a D-shaped configuration and a first or curved end portion 244 of the frame 242 is disposed adjacent a proximal end 206 of the flexible canopy 202. The frame 242 is disposed adjacent to a perimeter of the flexible shape of the perimeter of the flexible canopy 202. However, this is not meant to be limiting, and it will be understood that the frame **242** may be disposed at any location of the flexible canopy 202. In embodiments hereof, the frame 242 is configured to provide structural support to a proximal portion 248 of the flexible canopy 202. Further, the frame 242 serves to maintain coaptation angles between the flexible canopy 202 and the non-prolapsing leaflet or leaflets of the heart valve when the system 200 is in a deployed configuration and the heart valve is in a closed configuration. While shown with a specific shape, the frame **242** may have other shapes including but not limited to an ellipse, a circle, or any other shape suitable for the purposes described herein. Further, embodiments of the frame 242 may include additional struts or other strengthening members. The frame **242** may be formed of materials such as, but not limited to nickel titanium alloys (e.g. NITINOL), stainless steel, or other suitable materials. The frame 242 may be sewn into the flexible canopy 202 or may be coupled to the flexible canopy 202 by any other suitable method. In an embodiment, the frame 242 is attached to a plurality of proximal anchors 236.

In the embodiment of FIG. 7A, the frame 242 is configured to be disposed only on the atrial side of the native mitral valve when the system 200 is in a deployed configuration in situ. When the frame **242** is disposed only on the atrial side of the native mitral valve, the flexible canopy 202 is permitted to have increased flexibility within the left ventricle. Further, with the frame 242 disposed only on the atrial side of the native mitral valve, there are no relatively rigid or stiff elements of the frame 242 within the left ventricle LV that have potential to damage the chordae or other native anatomy within the left ventricle LV. In an alternate embodiment, the frame 242 may extend distally into the adjacent ventricle.

The elongated tether 204 of FIG. 7A is similar to the elongated tether 104 of FIG. 3A, except that the configuration or arrangement of the elastic and inelastic portions 224, 226, respectively are reversed from the configuration of the elongated tether 104 shown in FIG. 3A. More particularly, in the embodiment of FIG. 7A, the elastic portion 224 is disposed distal of the inelastic portion 226. The elastic portion 224 includes a proximal end 228 and a distal end 230. In the embodiment of FIG. 7A, the elastic portion 224 is a helical spring. As with the elastic portion 124 of FIG. 3A, the elastic portion 224 is configured to impart a tension force on the flexible canopy 202 as previously described with respect to the elastic portion 124 of FIG. 3A, and therefore is not described in detail with respect to FIG. 7A.

The configuration of the inelastic portion 226 of the elongated tether 204 of FIG. 7A includes a proximal end 232 coupled to the distal end 208 of the flexible canopy 202, a distal end 234 of the inelastic portion 226 coupled to the

proximal end 228 of the elastic portion 224, and the distal end 230 of the elastic portion 224 coupled to the ventricle as previously described with respect to the distal end 134 of FIGS. 4-6. While the inelastic portion 226 and the elastic portion 224 are positioned at opposite ends of the elongated tether 204 than the elastic portion 124 and the inelastic portion 126 of the elongated tether 104 of FIG. 3A, it will be understood that applying and adjusting the tension force on the flexible canopy 202 is similarly accomplished by lengthening or shortening the length of the elongated tether 10 **204**.

While described herein with one (1) spring elastic portion 224, in an alternative embodiment, an elongated tether 204' includes two (2) spring elastic portions 224a and 224b, disposed at the proximal end 232' and the distal end 234', 15 respectively, of the inelastic portion 226', as shown in FIG. 7B. The two spring elastic portions 224a and 224b help to ensure that dynamic movement of the flexible canopy 202 is permitted in situ.

illustrating method steps of treating regurgitation at a mitral valve MV via a transseptal approach for delivering and deploying the system 100 of FIG. 3 in accordance with an embodiment hereof. Access to the mitral valve MV can be accomplished through a patient's vasculature in a percuta- 25 neous manner. In an embodiment, the approach to the mitral valve is antegrade and may be accomplished via entry into the left atrium by crossing the interatrial septum. As is known in the art, a guidewire (not shown) may be advanced intravascularly using any number of techniques, e.g., 30 through the inferior vena cava or superior vena cava (FIG. 1), into the right atrium RA through a penetration hole cut in the inter-atrial septum (not shown) and into the left atrium LA (FIG. 1). A guide catheter (not shown) may be advanced along the guidewire and into the right atrium RA, through 35 the penetration hole in the inter-atrial septum, and into the left atrium LA. The guide catheter may have a pre-shaped or steerable distal end to shape or steer the guide catheter such that it will direct a delivery catheter toward the mitral valve MV.

Alternatively, the mitral valve may also be accessed via a transatrial approach for e.g., directly through an incision in the left atrium LA. Access to the heart may be obtained through an intercostal incision in the chest without removing ribs, and a guiding catheter (not shown) may be placed into 45 the left atrium LA through an atrial incision sealed with a purse-string suture. A delivery catheter may then be advanced through the guiding catheter to the mitral valve. Alternatively, the delivery catheter may include a guidewire lumen such that it may be tracked over a guidewire and 50 placed directly through the atrial incision without the use of a guiding catheter.

Referring to FIG. 8, a distal segment 303 of a delivery catheter 301 is shown positioned in the left atrium LA. The into the left atrium LA with the system 100 in a delivery configuration, in which the system 100 is radially compressed and disposed within the distal segment 303 of the delivery catheter 301. Intravascular access to the right atrium RA may be achieved via a percutaneous access site 60 in a femoral, brachial, radial, or axillary artery. As will be understood by those knowledgeable in the art, a handle component (not visible in FIGS. 8-14), as well as some length of a proximal segment of the delivery catheter 301, are exposed externally of the patient for access by a clini- 65 cian. By manipulating the handle of the delivery catheter 301 from outside the vasculature, a clinician may advance

14

and remotely manipulate and steer the distal segment 303 of the delivery catheter 301 through the sometimes tortuous intravascular path. The distal segment 303 of the delivery catheter 301 may be distally advanced into the left atrium LA and positioned generally above (e.g., upstream) the mitral valve MV to deliver the system 100 to the mitral valve MV.

In a next delivery step shown in FIG. 9, three proximal anchors 136 are embedded in tissue at an annulus AN of the mitral valve MV. Embedding of each proximal anchor 136 at the annulus AN may be accomplished by various methods understood by those knowledgeable in the art. For example, and not by way of limitation, each proximal anchor 136 may be a helical anchor, rotated by a respective proximal anchor shaft 305 of the delivery catheter 301 to embed each proximal anchor 136 into tissue at the annulus AN. Each proximal anchor shaft 305 may be a shaft, rod, or lead as described, for example, in U.S. Pat. No. 3,974,834 or 4,046,151, each of which has previously been incorporated FIGS. 8-14 are sectional cut-away views of a heart HE 20 by reference in its entirety. Once each proximal anchor 136 is embedded at the annulus AN, the proximal anchor 136 is released from the respective proximal anchor shaft 305.

> In the embodiment of FIG. 9, each proximal anchor 136 is pre-attached to the flexible canopy 102 prior to delivery with the delivery catheter 301. Thus, once the proximal anchors 136 are embedded at the annulus AN and each proximal anchor 136 is released from the respective proximal anchor shaft 305, the proximal end 106 of the flexible canopy 102 remains attached to each of the proximal anchors 136 at the annulus AN, as shown in FIG. 10. The proximal end 106 is attached to the plurality of proximal anchors 136 to effectively anchor or secure the proximal end 106 of the flexible canopy 102 to the annulus AN of the native mitral valve MV.

While described herein with the flexible canopy 102 pre-attached to the plurality of proximal anchors 136 prior to delivery by the delivery catheter 301, this is by way of example and not limitation. It will be understood that the flexible canopy 102 can alternatively be coupled to the 40 plurality of proximal anchors **136** after each of the proximal anchors 136 has been embedded at the annulus AN of the native mitral valve MV. For example, and not by way of limitation, the flexible canopy 102 may include a plurality of eyelets attached thereto with each proximal anchor shaft 305 disposed through a corresponding eyelet. The flexible canopy 102 can be deployed from the delivery catheter 301 by a push shaft or other device, and each eyelet and the flexible canopy 102 slide distally along the respective plurality of proximal anchor shafts 305 to couple to the corresponding proximal anchors 136. Once the flexible canopy 102 is coupled to the plurality of proximal anchors 136, each proximal anchor 136 is released by the respective proximal anchor shaft 305.

As shown in FIG. 11, in a next step the distal anchor 138 delivery catheter 301 is delivered through the vasculature 55 is embedded in tissue within the left ventricle LV with a distal anchor shaft 307. Embedding of the distal anchor 138 may be accomplished by various methods understood by those knowledgeable in the art. For example, and not by way of limitation, the distal anchor 138 may be a helical anchor, rotated by the distal anchor shaft 307 to embed the distal anchor 138 in an apex AP of the left ventricle LV. The distal anchor shaft 307 may be a shaft, rod, or lead as described, for example, in U.S. Pat. No. 3,974,834 or 4,046,151 assigned to Medtronic, Inc., each of which has previously been incorporated by reference in its entirety. While shown with the distal anchor 138 embedded in tissue at an apex AP of the left ventricle LV, this is by way of example and not

limitation. As previously described, the location of the distal anchor 138 within the left ventricle LV may be determined based upon the angle of the flexible canopy 102 in relation to the anterior leaflet AL to achieve optimal coaptation between the flexible canopy 102 and the anterior leaflet AL 5 to minimize or eliminate regurgitation. Once the distal anchor 138 is embedded at the desired location of the left ventricle LV, the distal anchor 138 is released from the distal anchor shaft 307.

In the embodiment of FIG. 11, the distal anchor 138 is 10 pre-attached to the elongated tether 104 prior to delivery with the delivery catheter 301. Accordingly, once the distal anchor 138 is embedded in the left ventricle LV and the distal anchor 138 is released from the distal anchor shaft **307**, the distal end **122** of the elongated tether **104** is attached 15 to the distal anchor **138**, as shown in FIG. **12**. The distal end **122** is attached to the distal anchor **138** to effectively secure or anchor the distal end 122 of the elongated tether 104 to the left ventricle LV.

Although the elongated tether **104** has been described as 20 coupled to the distal anchors 138 prior to delivery by the delivery catheter 301, this is by way of example and not limitation. It will be understood that the elongated tether 104 may alternatively be delivered separately and coupled to the distal anchor 138 after the distal anchor 138 has been 25 embedded in the left ventricle LV. For example, and not by way of limitation, the elongated tether 104 can include an eyelet at the distal end 122 with the distal anchor shaft 307 disposed through the eyelet of the elongated tether **104**. The elongated tether 104 can be deployed from the delivery 30 catheter 301 by a push shaft or other device, and the eyelet and the elongated tether 104 slid distally along the distal anchor shaft 307 to couple to the eyelet of the elongated tether 104 to the distal anchor 138. Once the elongated tether is released by the distal anchor shaft 307.

When the proximal end 106 of the flexible canopy 102 is coupled to the annulus AN and the distal end 122 of the elongated tether 104 is coupled to the left ventricle LV, with the flexible canopy 102 overlaying the posterior leaflet PL, 40 tension is applied and/or adjusted as described above with respect to FIGS. 4 and 5 to apply a tension force on the flexible canopy 102. More precisely, as described above in more detail, the elastic portion 124 of the elongated tether 104 is placed under spring tension and the spring tension on 45 the elastic portion 124 is transferred to the distal end 108 of the flexible canopy 102 as a second tension force TF2 as indicated by the arrow TF2. The second tension force TF2 on the flexible canopy **102** prevents the posterior leaflet PL from prolapsing and insures coaptation of the flexible 50 canopy 102 with the anterior leaflet AL, as shown in FIG. 13.

In a next step, the mitral valve MV is checked for valvular regurgitation. Checking for regurgitation of the mitral valve MV may be accomplished by various methods including, but not limited to echocardiogram, to visualize placement of the 55 flexible canopy 102 and prolapse of the posterior leaflet PL of the mitral valve MV. Accordingly, an echogenic coating may be applied to one or more integral portions of the system 100 to aid in visualization. When the mitral valve MV has been checked for valvular regurgitation, the treating 60 clinician may further adjust the tension force on the flexible canopy 102 to minimize valvular regurgitation and optimize coaptation of the flexible canopy 102 with the anterior leaflet AL, as shown in FIG. 14. The steps of checking for valvular regurgitation and readjusting the tension force on the flex- 65 deployed configuration, the system comprising: ible canopy 102 may be repeated to optimize performance of the repaired mitral valve MV. Following delivery, deploy-

16

ment and adjustment of the system 100 at the mitral valve MV (or other desired valve location), the delivery catheter **301** and remaining guidewire (if any) may be removed from the heart 10 and out of the body of the patient.

Image guidance, enhanced echogenicity, or other methods may be used to aid the clinician's delivery and positioning of the system 100. Image guidance, e.g., intracardiac echocardiography (ICE), fluoroscopy, computed tomography (CT), intravascular ultrasound (IVUS), optical coherence tomography (OCT), or another suitable guidance modality, or combination thereof, may be used to aid the clinician's positioning and manipulation of the system 100 at the target native valve region. For example, such image guidance technologies can be used to aid in determining the positioning of the flexible canopy 102 with relation to the underlying, prolapsing native leaflet. In some embodiments, image guidance components (e.g., IVUS, OCT) can be coupled to the distal portion of the delivery catheter 301, a guide catheter, or both to provide three-dimensional images of the area proximate to the target heart valve region to facilitate positioning, orienting and/or deployment of the system 100 within the heart valve region. Accordingly, an echogenic coating may be applied to components of the system to aid in visualization.

Various method steps described above for delivery and deployment of embodiments of the system within a native heart valve of a patient may also be interchanged to form additional embodiments of the present technology. For example, while the method steps described above are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.

Furthermore, while the delivery catheter described above 104 is coupled to the distal anchor 138, the distal anchor 138 35 is discussed as being suitable for delivering embodiments of the system to the native mitral valve using a transseptal approach, it will be understood that the delivery catheter may also be suitable for delivering systems for repair of other heart valves (e.g., pulmonary valve, tricuspid valve, etc.) and utilizing other approaches (e.g. retrograde, antegrade). Various arrangements of the delivery catheters suitable for use with embodiments of systems and methods described herein may also be used to deliver other therapeutic or medical tools within body lumens.

While various embodiments have been described above, it should be understood that they have been presented only as illustrations and examples of the present technology, and not by way of limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the present technology. Thus, the breadth and scope of the present technology should not be limited by any of the above-described embodiments, but should be defined only in accordance with the appended claims and their equivalents. It will also be understood that each feature of each embodiment discussed herein, and of each reference cited herein, may be used in combination with the features of any other embodiment. All patents and publications discussed herein are incorporated by reference herein in their entirety.

What is claimed is:

- 1. A system for treating valvular regurgitation in a heart valve, the system including a delivery configuration and a
 - a flexible canopy including a first surface and a second surface opposite the first surface;

- an elongated tether configured to be placed under tension in situ, the elongated tether including an elastic portion and an inelastic portion coupled to the elastic portion, wherein the elastic portion is at least as long as the inelastic portion with a ratio of the elastic portion to the 5 inelastic portion being between 50/50 and 70/30 and a proximal end of the elongated tether is attached to a distal end of the flexible canopy; and
- a distal anchor configured to be embedded into tissue of a ventricle, wherein a distal end of the elongated tether 10 is coupled to the distal anchor,
- wherein when the system is in the deployed configuration, a proximal end of the flexible canopy is anchored to an annulus of the heart valve and the distal end of the elongated tether is anchored to tissue of a ventricle via 15 the distal anchor such that the first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve, and the elongated tether is placed under tension such that the system is configured to prevent the first leaflet of the heart valve from 20 prolapsing, and to permit a portion of the second surface of the flexible canopy to coapt with at least an opposing mating portion of a second leaflet of the heart valve.
- 2. The system of claim 1, wherein when the first surface 25 of the flexible canopy overlays the first leaflet of the heart valve, the first surface of the flexible canopy is substantially in contact with between forty and ninety percent of the underlying first surface of the first leaflet of the heart valve.
- 3. The system of claim 1, wherein the flexible canopy 30 does not extend into the ventricle when the system is in the deployed configuration.
- 4. The system of claim 1, wherein the inelastic portion of the elongated tether is positioned distal of the elastic portion of the elongated tether.
- 5. The system of claim 1, wherein the elastic portion of the elongated tether is positioned distal of the inelastic portion of the elongated tether.
- 6. The system of claim 1, wherein the elastic portion of the elongated tether is longer than the inelastic portion of the elongated tether.
- 7. The system of claim 1, wherein the elastic portion of the elongated tether is a spring.
- 8. The system of claim 1, further comprising: a frame coupled to a portion of the flexible canopy.
- 9. The system of claim 8, wherein the frame does not extend into the ventricle when the system is in the deployed configuration.
- 10. The system of claim 1, wherein the flexible canopy is unsupported and does not include a frame coupled thereto. 50
- 11. The system of claim 1, wherein the flexible canopy extends into the ventricle when the system is in the deployed configuration.
- 12. A system for treating valvular regurgitation in a heart valve, the system including a delivery configuration and a 55 first leaflet of the heart valve. deployed configuration, the system comprising:

 16. The system of claim 13
 - a flexible canopy including a first surface and a second surface opposite the first surface; and
 - an elongated tether configured to be placed under tension in situ, the elongated tether including an elastic portion 60 and an inelastic portion coupled to the elastic portion, wherein the elastic portion is at least as long as the inelastic portion and a proximal end of the elongated tether is attached to a distal end of the flexible canopy, wherein when the system is in the deployed configuration, 65 a proximal end of the flexible canopy is anchored to an annulus of the heart valve and a distal end of the

18

elongated tether is anchored to tissue of a ventricle such that the first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve, and the elongated tether is placed under tension such that the system is configured to prevent the first leaflet of the heart valve from prolapsing, and to permit a portion of the second surface of the flexible canopy to coapt with at least an opposing mating portion of a second leaflet of the heart valve, and

wherein the first surface of the flexible canopy includes at least one micro-barb and the at least one micro-barb is configured to couple the first surface of the flexible canopy to the underlying first surface of the first leaflet of the heart valve.

- 13. A system for treating valvular regurgitation in a heart valve, the system including a delivery configuration and a deployed configuration, the system comprising:
 - a flexible canopy including a first surface and a second surface opposite the first surface, wherein the flexible canopy is unsupported and does not include a frame coupled thereto; and
 - an elongated tether configured to be placed under tension in situ, the elongated tether including an elastic portion and an inelastic portion coupled to the elastic portion, wherein a ratio of the elastic portion to the inelastic portion is between 50/50 and 70/30, and wherein a proximal end of the elongated tether is attached to a distal end of the flexible canopy; and
 - a distal anchor configured to be embedded into tissue of a ventricle, wherein a distal end of the elongated tether is coupled to the distal anchor,
 - wherein when the system is in the deployed configuration, a proximal end of the flexible canopy is anchored to an annulus of the heart valve and the distal end of the elongated tether is anchored to tissue of a ventricle via the distal anchor such that the first surface of the flexible canopy overlays an underlying first surface of a first leaflet of the heart valve, and the elongated tether is placed under tension such that the system is configured to prevent the first leaflet of the heart valve from prolapsing, and to permit a portion of the second surface of the flexible canopy to coapt with at least an opposing mating portion of a second leaflet of the heart valve.
- 14. The system of claim 13, wherein when the first surface of the flexible canopy overlays the first leaflet of the heart valve, the first surface of the flexible canopy is substantially in contact with between forty and ninety percent of the underlying first surface of the first leaflet of the heart valve.
- 15. The system of claim 13, wherein the first surface of the flexible canopy includes at least one micro-tine and the at least one micro-tine is configured to couple the first surface of the flexible canopy to the underlying first surface of the first leaflet of the heart valve.
- 16. The system of claim 13, wherein the flexible canopy does not extend into the ventricle when the system is in the deployed configuration.
- 17. The system of claim 13, wherein the flexible canopy extends into the ventricle when the system is in the deployed configuration.
- 18. The system of claim 13, wherein the inelastic portion of the elongated tether is positioned distal of the elastic portion of the elongated tether.
- 19. The system of claim 13, wherein the elastic portion of the elongated tether is positioned distal of the inelastic portion of the elongated tether.

20

20. The system of claim 13, wherein the elastic portion of the elongated tether is longer than the inelastic portion of the elongated tether.

* * * * *